Eupraxia Pharmaceuticals (EPRX) Exchange Rate Effect (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Exchange Rate Effect of -$448176.0 for Q1 2026, down 1422.29% quarter-over-quarter from $33894.0 in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Exchange Rate Effect (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Exchange Rate Effect for 4 consecutive years, with -$448176.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Exchange Rate Effect changed N/A year-over-year to -$448176.0; the TTM figure through Mar 2026 stood at -$903289.0 (changed N/A YoY), while the FY2025 annual figure was $544813.0, up 127.87% from the prior year.
- Exchange Rate Effect fell to -$448176.0 in Q1 2026 per EPRX's latest filing, from $33894.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $786490.0 in Q4 2023 and bottomed at -$1.3 million in Q4 2024.
- Historically, Exchange Rate Effect has averaged -$225822.2 across 4 years, with a median of -$207141.0 in 2025.
- Annual changes were most pronounced in 2024 — Exchange Rate Effect plunged 262.18% — and 2025, when it surged 102.66%.
- Eupraxia Pharmaceuticals' Exchange Rate Effect stood at $786490.0 in 2023, then slumped by 262.18% to -$1.3 million in 2024, then soared by 102.66% to $33894.0 in 2025, then slumped by 1422.29% to -$448176.0 in 2026.
- Business Quant data shows EPRX's Exchange Rate Effect at -$448176.0 in Q1 2026, $33894.0 in Q4 2025, and -$1.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | -448,176.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -448,176.00 |
| Mar 31, 2026 | -448,176.00 |
| Dec 31, 2025 | 33,894.00 |
| Dec 31, 2025 | 33,894.00 |
| Dec 31, 2024 | -1.28 Mn |
| Dec 31, 2024 | -1.28 Mn |
| Dec 31, 2023 | 786,490.00 |
| Dec 31, 2023 | 786,490.00 |